Published in Pharm Res on January 15, 2013
In vivo performance of a novel fluorinated magnetic resonance imaging agent for functional analysis of bile acid transport. Mol Pharm (2014) 0.89
Design and evaluation of a novel trifluorinated imaging agent for assessment of bile acid transport using fluorine magnetic resonance imaging. J Pharm Sci (2014) 0.81
Using Multi-fluorinated Bile Acids and In Vivo Magnetic Resonance Imaging to Measure Bile Acid Transport. J Vis Exp (2016) 0.75
Targeting bile-acid signalling for metabolic diseases. Nat Rev Drug Discov (2008) 4.43
Bile acids: regulation of synthesis. J Lipid Res (2009) 4.31
FLASH imaging: rapid NMR imaging using low flip-angle pulses. 1986. J Magn Reson (2011) 3.71
Endocrine functions of bile acids. EMBO J (2006) 3.03
Targeted deletion of the ileal bile acid transporter eliminates enterohepatic cycling of bile acids in mice. J Biol Chem (2003) 2.26
19F: a versatile reporter for non-invasive physiology and pharmacology using magnetic resonance. Curr Med Chem (2005) 1.79
Primary bile acid malabsorption caused by mutations in the ileal sodium-dependent bile acid transporter gene (SLC10A2). J Clin Invest (1997) 1.75
Fluorine (19F) MRS and MRI in biomedicine. NMR Biomed (2010) 1.60
Hepatic uptake of the magnetic resonance imaging contrast agent Gd-EOB-DTPA: role of human organic anion transporters. Drug Metab Dispos (2010) 1.53
Bile acid malabsorption in persistent diarrhoea. J R Coll Physicians Lond (2001) 1.49
Bile acids and signal transduction: role in glucose homeostasis. Cell Signal (2008) 1.45
Rapid NMR imaging of dynamic processes using the FLASH technique. Magn Reson Med (1986) 1.40
Development of stably transfected monolayer overexpressing the human apical sodium-dependent bile acid transporter (hASBT). Pharm Res (2005) 1.38
Bile acids: regulation of apoptosis by ursodeoxycholic acid. J Lipid Res (2009) 1.36
Idiopathic bile acid malabsorption--a review of clinical presentation, diagnosis, and response to treatment. Gut (1991) 1.33
Rapid screening of increased bile acid deconjugation and bile acid malabsorption by means of the glycine-l-(14C) cholylglycine assay. Scand J Gastroenterol (1973) 1.33
Hepatic transport of bile salts. Semin Liver Dis (2000) 1.31
Serum 7 alpha-hydroxy-4-cholesten-3-one and selenohomocholyltaurine (SeHCAT) whole body retention in the assessment of bile acid induced diarrhoea. Eur J Gastroenterol Hepatol (1996) 1.31
Computational models for drug inhibition of the human apical sodium-dependent bile acid transporter. Mol Pharm (2009) 1.26
Interaction of native bile acids with human apical sodium-dependent bile acid transporter (hASBT): influence of steroidal hydroxylation pattern and C-24 conjugation. Pharm Res (2006) 1.25
Enterohepatic circulation in man of a gamma-emitting bile-acid conjugate, 23-selena-25-homotaurocholic acid (SeHCAT). J Nucl Med (1982) 1.24
Absence of dysfunctional ileal sodium-bile acid cotransporter gene mutations in patients with adult-onset idiopathic bile acid malabsorption. Scand J Gastroenterol (2001) 1.20
Symmetry-guided design and fluorous synthesis of a stable and rapidly excreted imaging tracer for (19)F MRI. Angew Chem Int Ed Engl (2009) 1.19
Role of the intestinal bile acid transporters in bile acid and drug disposition. Handb Exp Pharmacol (2011) 1.14
Effectiveness and tolerability of colesevelam hydrochloride for bile-acid malabsorption in patients with cancer: a retrospective chart review and patient questionnaire. Clin Ther (2009) 1.10
Bias in estimation of transporter kinetic parameters from overexpression systems: Interplay of transporter expression level and substrate affinity. J Pharmacol Exp Ther (2006) 1.10
Dissolution media simulating the intralumenal composition of the small intestine: physiological issues and practical aspects. J Pharm Pharmacol (2004) 1.08
Bile acid malabsorption in inflammatory bowel disease: assessment by serum markers. Inflamm Bowel Dis (2010) 1.04
Structural determinants for transport across the intestinal bile acid transporter using C-24 bile acid conjugates. Mol Pharm (2010) 1.01
Method to screen substrates of apical sodium-dependent bile acid transporter. AAPS J (2008) 1.00
Bile acid malabsoption: a forgotten diagnosis? Clin Med (2010) 0.95
Influence of the amino acid moiety on deconjugation of bile acid amidates by cholylglycine hydrolase or human fecal cultures. J Lipid Res (1986) 0.93
Description and simulation of a physiological pharmacokinetic model for the metabolism and enterohepatic circulation of bile acids in man. Cholic acid in healthy man. J Clin Invest (1983) 0.92
Chronic diarrhea due to excessive bile acid synthesis and not defective ileal transport: a new syndrome of defective fibroblast growth factor 19 release. Clin Gastroenterol Hepatol (2009) 0.92
Structural requirements of bile acid transporters: C-3 and C-7 modifications of steroidal hydroxyl groups. Eur J Pharm Sci (2012) 0.90
Determination of intralumenal individual bile acids by HPLC with charged aerosol detection. J Lipid Res (2008) 0.88
Synthesis and in vitro evaluation of gabapentin prodrugs that target the human apical sodium-dependent bile acid transporter (hASBT). J Pharm Sci (2010) 0.85
In vivo magnetic resonance imaging to detect biliary excretion of 19F-labeled drug in mice. Drug Metab Dispos (2011) 0.83
Bile acid binding in plasma: the importance of lipoproteins. FEBS Lett (1985) 0.82
Quality assessment of colonoscopic cecal intubation: an analysis of 6 years of continuous practice at a university hospital. Am J Gastroenterol (2006) 3.49
Biopharmaceutics classification system: the scientific basis for biowaiver extensions. Pharm Res (2002) 1.74
Rapid identification of P-glycoprotein substrates and inhibitors. Drug Metab Dispos (2006) 1.68
The use of BDDCS in classifying the permeability of marketed drugs. Pharm Res (2008) 1.57
The absence of p53 promotes metastasis in a novel somatic mouse model for hepatocellular carcinoma. Mol Cell Biol (2005) 1.52
Lack of medication dose uniformity in commonly split tablets. J Am Pharm Assoc (Wash) (2002) 1.46
Diffusion kurtosis as an in vivo imaging marker for reactive astrogliosis in traumatic brain injury. Neuroimage (2011) 1.45
Bile acid-induced proliferation of a human colon cancer cell line is mediated by transactivation of epidermal growth factor receptors. Biochem Pharmacol (2005) 1.44
Effects of nonionic surfactants on membrane transporters in Caco-2 cell monolayers. Eur J Pharm Sci (2002) 1.43
Muscarinic receptors and ligands in cancer. Am J Physiol Cell Physiol (2008) 1.42
Comments on effect of food on early drug exposure from extended-release stimulants: results from the Concerta, Adderall XR food evaluation study. Curr Med Res Opin (2002) 1.41
Development of stably transfected monolayer overexpressing the human apical sodium-dependent bile acid transporter (hASBT). Pharm Res (2005) 1.38
Apical sodium dependent bile acid transporter (ASBT, SLC10A2): a potential prodrug target. Mol Pharm (2006) 1.38
Human cecal bile acids: concentration and spectrum. Am J Physiol Gastrointest Liver Physiol (2007) 1.35
Increased acyclovir oral bioavailability via a bile acid conjugate. Mol Pharm (2004) 1.32
Matrix metalloproteinase-7-catalyzed release of HB-EGF mediates deoxycholyltaurine-induced proliferation of a human colon cancer cell line. Biochem Pharmacol (2006) 1.30
Genetic ablation of M3 muscarinic receptors attenuates murine colon epithelial cell proliferation and neoplasia. Cancer Res (2008) 1.29
Transactivation of the epidermal growth factor receptor mediates cholinergic agonist-induced proliferation of H508 human colon cancer cells. Cancer Res (2003) 1.28
Activation of muscarinic receptor signaling by bile acids: physiological and medical implications. Dig Dis Sci (2003) 1.28
Computational models for drug inhibition of the human apical sodium-dependent bile acid transporter. Mol Pharm (2009) 1.26
Interaction of native bile acids with human apical sodium-dependent bile acid transporter (hASBT): influence of steroidal hydroxylation pattern and C-24 conjugation. Pharm Res (2006) 1.25
Acetylcholine-induced activation of M3 muscarinic receptors stimulates robust matrix metalloproteinase gene expression in human colon cancer cells. Am J Physiol Gastrointest Liver Physiol (2009) 1.19
Acetylcholine release by human colon cancer cells mediates autocrine stimulation of cell proliferation. Am J Physiol Gastrointest Liver Physiol (2008) 1.19
Simultaneous perfusion and BOLD imaging using reverse spiral scanning at 3T: characterization of functional contrast and susceptibility artifacts. Magn Reson Med (2002) 1.16
Muscarinic receptor subtype-3 gene ablation and scopolamine butylbromide treatment attenuate small intestinal neoplasia in Apcmin/+ mice. Carcinogenesis (2011) 1.16
The solute carrier family 10 (SLC10): beyond bile acid transport. Mol Aspects Med (2013) 1.11
Meeting report: applied biopharmaceutics and quality by design for dissolution/release specification setting: product quality for patient benefit. AAPS J (2010) 1.11
Bias in estimation of transporter kinetic parameters from overexpression systems: Interplay of transporter expression level and substrate affinity. J Pharmacol Exp Ther (2006) 1.10
Impact of Biopharmaceutics Classification System-based biowaivers. Mol Pharm (2010) 1.09
Novel inhibitors of human organic cation/carnitine transporter (hOCTN2) via computational modeling and in vitro testing. Pharm Res (2009) 1.09
Pharmacokinetics and Biodistribution of (86)Y-Trastuzumab for (90)Y dosimetry in an ovarian carcinoma model: correlative MicroPET and MRI. J Nucl Med (2003) 1.09
Intrathecal tripeptidyl-peptidase 1 reduces lysosomal storage in a canine model of late infantile neuronal ceroid lipofuscinosis. Mol Genet Metab (2011) 1.08
MRI of mouse models for gliomas shows similarities to humans and can be used to identify mice for preclinical trials. Neoplasia (2002) 1.08
Murine S factors for liver, spleen, and kidney. J Nucl Med (2003) 1.07
3',5'-Cyclic diguanylic acid (c-di-GMP) inhibits basal and growth factor-stimulated human colon cancer cell proliferation. Biochem Biophys Res Commun (2005) 1.07
Functional interaction of lithocholic acid conjugates with M3 muscarinic receptors on a human colon cancer cell line. Biochim Biophys Acta (2002) 1.07
Molecular switch controlling the binding of anionic bile acid conjugates to human apical sodium-dependent bile acid transporter. J Med Chem (2010) 1.07
Influence of charge and steric bulk in the C-24 region on the interaction of bile acids with human apical sodium-dependent bile acid transporter. Mol Pharm (2006) 1.03
Distance from Skin to Epidural Space: Correlation with Body Mass Index (BMI). J Anaesthesiol Clin Pharmacol (2011) 1.03
Selective interaction of bile acids with muscarinic receptors: a case of molecular mimicry. Eur J Pharmacol (2002) 1.02
Determination of the glutamate-glutamine cycling flux using two-compartment dynamic metabolic modeling is sensitive to astroglial dilution. J Cereb Blood Flow Metab (2008) 1.01
Muscarinic receptor agonists stimulate human colon cancer cell migration and invasion. Am J Physiol Gastrointest Liver Physiol (2011) 1.01
Structural determinants for transport across the intestinal bile acid transporter using C-24 bile acid conjugates. Mol Pharm (2010) 1.01
Adaptive dielectric liquid lens. Opt Express (2008) 1.01
Method to screen substrates of apical sodium-dependent bile acid transporter. AAPS J (2008) 1.00
Akt-dependent NF-kappaB activation is required for bile acids to rescue colon cancer cells from stress-induced apoptosis. Exp Cell Res (2008) 1.00
Structure-activity relationship for FDA approved drugs as inhibitors of the human sodium taurocholate cotransporting polypeptide (NTCP). Mol Pharm (2013) 0.99
Aqueous and cosolvent solubility data for drug-like organic compounds. AAPS J (2005) 0.98
Recent advances in ligand-based drug design: relevance and utility of the conformationally sampled pharmacophore approach. Curr Comput Aided Drug Des (2011) 0.97
Vasodilatory effects of cholinergic agonists are greatly diminished in aorta from M3R-/- mice. Eur J Pharmacol (2004) 0.96
Bile acids regulate cardiovascular function. Clin Transl Sci (2011) 0.95
Single-shot interleaved z-shim EPI with optimized compensation for signal losses due to susceptibility-induced field inhomogeneity at 3 T. Neuroimage (2002) 0.95
Src-mediated aryl hydrocarbon and epidermal growth factor receptor cross talk stimulates colon cancer cell proliferation. Am J Physiol Gastrointest Liver Physiol (2012) 0.94
Thalamocortical asynchrony in conditions of spinal cord injury pain in rats. J Neurosci (2012) 0.94
Computational models to assign biopharmaceutics drug disposition classification from molecular structure. Pharm Res (2007) 0.94
Surfactant-mediated dissolution: contributions of solubility enhancement and relatively low micelle diffusivity. J Pharm Sci (2004) 0.94
Muscarinic receptor agonists stimulate matrix metalloproteinase 1-dependent invasion of human colon cancer cells. Biochem Biophys Res Commun (2011) 0.94
Deoxycholyltaurine rescues human colon cancer cells from apoptosis by activating EGFR-dependent PI3K/Akt signaling. J Cell Physiol (2008) 0.93
Ondansetron can enhance cisplatin-induced nephrotoxicity via inhibition of multiple toxin and extrusion proteins (MATEs). Toxicol Appl Pharmacol (2013) 0.91
Cholinergic agonist-induced pepsinogen secretion from murine gastric chief cells is mediated by M1 and M3 muscarinic receptors. Am J Physiol Gastrointest Liver Physiol (2005) 0.91
Temporal changes in magnetic resonance imaging in the mdx mouse. BMC Res Notes (2013) 0.91
A quantitative structure-property relationship for predicting drug solubility in PEG 400/water cosolvent systems. Pharm Res (2004) 0.90
Quantitative structure activity relationship for inhibition of human organic cation/carnitine transporter. Mol Pharm (2010) 0.90
Structural requirements of bile acid transporters: C-3 and C-7 modifications of steroidal hydroxyl groups. Eur J Pharm Sci (2012) 0.90
Impact of impurity on kinetic estimates from transport and inhibition studies. J Pharmacol Exp Ther (2008) 0.90
Deoxycholyltaurine-induced vasodilation of rodent aorta is nitric oxide- and muscarinic M(3) receptor-dependent. Eur J Pharmacol (2005) 0.89
In vivo performance of a novel fluorinated magnetic resonance imaging agent for functional analysis of bile acid transport. Mol Pharm (2014) 0.89
Inhibition requirements of the human apical sodium-dependent bile acid transporter (hASBT) using aminopiperidine conjugates of glutamyl-bile acids. Pharm Res (2009) 0.89
Midazolam exhibits characteristics of a highly permeable P-glycoprotein substrate. Pharm Res (2003) 0.89
Theoretical analysis of carbon-13 magnetization transfer for in vivo exchange between alpha-ketoglutarate and glutamate. NMR Biomed (2006) 0.88
P-glycoprotein efflux and other factors limit brain amyloid beta reduction by beta-site amyloid precursor protein-cleaving enzyme 1 inhibitors in mice. J Pharmacol Exp Ther (2008) 0.88
A survey of credentialing practices of gastrointestinal endoscopy centers in the United States. J Clin Gastroenterol (2005) 0.88
Hepatitis C knowledge among primary care residents: is our teaching adequate for the times? Am J Gastroenterol (2004) 0.88
Caveolins sequester FA on the cytoplasmic leaflet of the plasma membrane, augment triglyceride formation, and protect cells from lipotoxicity. J Lipid Res (2010) 0.88
Computational model for predicting chemical substituent effects on passive drug permeability across parallel artificial membranes. Mol Pharm (2008) 0.87
Cholinergic muscarinic receptor activation augments murine intestinal epithelial cell proliferation and tumorigenesis. BMC Cancer (2013) 0.87
Deoxycholic acid conjugates are muscarinic cholinergic receptor antagonists. Pharmacology (2002) 0.87
A nuclear localized protein ZCCHC9 is expressed in cerebral cortex and suppresses the MAPK signal pathway. J Genet Genomics (2008) 0.87
Heterozygosity for factor V Leiden and G20210A prothrombin genotypes in a patient with mesenteric vein thrombosis. Dig Dis Sci (2002) 0.86
Muscarinic receptor signaling in colon cancer. Cancers (Basel) (2011) 0.86
Lithocholylcholine, a bile acid/acetylcholine hybrid, is a muscarinic receptor antagonist. J Pharmacol Exp Ther (2002) 0.86
Voltage-gated divalent currents in descending vasa recta pericytes. Am J Physiol Renal Physiol (2010) 0.86
Comparison of drug permeabilities and BCS classification: three lipid-component PAMPA system method versus Caco-2 monolayers. AAPS J (2010) 0.85